• Earlier in May 2026, Veracyte announced that its TrueMRD Monitoring Test for muscle-invasive bladder cancer recurrence had secured Medicare coverage from CMS under the MolDX program, with commercial availability set to begin on June 1, 2026.
• This decision not only supports clinical use of Veracyte’s first molecular residual disease offering, but also highlights its position as the only truly whole-genome MRD test currently available, potentially broadening its role in cancer care pathways.
• Next, we’ll examine how Medicare backing for Veracyte’s whole-genome TrueMRD platform may influence its existing cancer diagnostics investment narrative.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Veracyte Investment Narrative Recap

To own Veracyte, you need to believe that its genomic tests can keep gaining adoption while new offerings like TrueMRD gradually broaden the menu beyond Decipher and Afirma. Medicare coverage for the TrueMRD bladder cancer test directly addresses one key risk around payer access for new launches, but in the near term, the main catalyst and risk still center on execution and reimbursement stability in the existing core prostate and thyroid franchises.

The most relevant recent announcement alongside the TrueMRD news is Veracyte’s May 5 guidance raise, with 2026 revenue now expected at US$582 million to US$592 million. This update reflects management’s confidence in current test volumes and pricing, and it sets a higher bar for how quickly new programs like TrueMRD will need to contribute, even as legacy products remain the primary driver of results.

Yet even with Medicare support, investors should be aware that pricing pressure and revenue concentration risk remain...

Veracyte's narrative projects $712.5 million revenue and $96.2 million earnings by 2029.

Uncover how Veracyte's forecasts yield a $47.00 fair value, a 13% upside to its current price.

Exploring Other Perspectives

While the baseline view focuses on steady growth, the most optimistic analysts already projected about US$745.2 million revenue and US$111.8 million earnings by 2029, assuming MRD expansion meaningfully offsets pricing and concentration risks.

Explore 4 other fair value estimates on Veracyte - why the stock might be worth 42% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Veracyte research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Veracyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veracyte's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Capitalize on the AI infrastructure supercycle with our selection of the 44 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.